Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes

Biotechnology and Bioengineering

Volumn 108, Issue 10, 2011, Pages 2456-2467

  Gray, Sean A ^a   Barr, John R ^b   Kalb, Suzanne R ^b   Marks, James D ^c   Baird, Cheryl L ^d   Cangelosi, Gerard A ^a   Miller, Keith D ^d   Feldhaus, Michael J ^e  

^a SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^b NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^e Adimab Inc   (United States)

Author keywords

Affinity reagents; Antibodies; BoNT A; Molecular probes; ScFv; Yeast display

Indexed keywords

AFFINITY REAGENTS; BONT/A; MOLECULAR PROBES; SCFV; YEAST DISPLAY;

CLOSTRIDIUM; ESCHERICHIA COLI; MASS SPECTROMETRY; MONOCLONAL ANTIBODIES; PEPTIDES; TOXIC MATERIALS; YEAST;

ANTIGENS;

CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A BINDING DOMAIN; EPITOPE; MONOCLONAL ANTIBODY; NEUROTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BOTULINUM TOXIN A;

ANTIBODY LABELING; ANTIGEN BINDING; ARTICLE; BACTERIUM ISOLATION; BINDING AFFINITY; CLONE; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; EPITOPE MAPPING; ESCHERICHIA COLI; MASS SPECTROMETRY; NONHUMAN; SACCHAROMYCES CEREVISIAE; YEAST; ANTIBODY SPECIFICITY; BIOSYNTHESIS; CHEMISTRY; GENETICS; HUMAN; METABOLISM;

CLOSTRIDIUM BOTULINUM; SACCHAROMYCES CEREVISIAE;

ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BOTULINUM TOXINS, TYPE A; EPITOPES; HUMANS; SACCHAROMYCES CEREVISIAE; SINGLE-CHAIN ANTIBODIES;

EID: 80051780946     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.23196     Document Type: Article

References (31)

1. Amersdorfer P, Marks JD. 2000. Phage libraries for generation of anti-botulinum scFv antibodies. Methods Mol Biol 145: 219-240.
2. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. 1997. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun 65(9): 3743-3752.
3. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. 2002. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 20(11-12): 1640-1648.
4. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, McWilliams LG, Schmidt JG, Martinez RA, Ashley DL. 2005. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 11(10): 1578-1583.
5. Boyer AE, Moura H, Woolfitt AR, Kalb SR, McWilliams LG, Pavlopoulos A, Schmidt JG, Ashley DL, Barr JR. 2005. From the mouse to the mass spectrometer: Detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal Chem 77(13): 3916-3924.
6. Byrne MP, Smith TJ, Montgomery VA, Smith LA. 1998. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 66(10): 4817-4822.
7. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. 2006. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1(2): 755-768.
8. Cobey S, Pascual M. 2011. Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition. J Theor Biol 270(1): 80-87.
9. Ekong TA, Feavers IM, Sesardic D. 1997. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143(Pt 10): 3337-3347.
10. Feldhaus M, Siegel R. 2004. Flow cytometric screening of yeast surface display libraries. Methods Mol Biol 263: 311-332.
11. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD. 2003. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol 21(2): 163-170.
12. Gai SA, Wittrup KD. 2007. Yeast surface display for protein engineering and characterization. Curr Opin Struct Biol 17(4): 467-473.
13. Gray SA, Weigel KM, Miller KD, Ndung'u J, Buscher P, Tran T, Baird C, Cangelosi GA. 2010. Flow cytometry-based methods for assessing soluble scFv activities and detecting antigens in solution. Biotechnol Bioeng 105(5): 973-981.
14. Hallis B, James BA, Shone CC. 1996. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J Clin Microbiol 34(8): 1934-1938.
15. Kalb SR, Goodnough MC, Malizio CJ, Pirkle JL, Barr JR. 2005. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics. Anal Chem 77(19): 6140-6146.
16. Kalb SR, Moura H, Boyer AE, McWilliams LG, Pirkle JL, Barr JR. 2006. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. Anal Biochem 351(1): 84-92.
17. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. 2009. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS ONE 4(4): e5355.
18. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. 2010. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS ONE 5(8): e12237.
19. Kautter DA, Solomon HM. 1977. Collaborative study of a method for the detection of Clostridium botulinum and its toxins in foods. J Assoc Off Anal Chem 60(3): 541-545.
20. Kemmer G, Keller S. 2010. Nonlinear least-squares data fitting in Excel spreadsheets. Nat Protoc 5(2): 267-281.
21. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. 1998. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5(10): 898-902.
22. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. 2007. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol 365(1): 196-210.
23. Miller KD, Weaver-Feldhaus J, Gray SA, Siegel RW, Feldhaus MJ. 2005. Production, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli Protein Expr Purif 42(2): 255-267.
24. Mullaney BP, Pallavicini MG, Marks JD. 2001. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun 69(10): 6511-6514.
25. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. 2005. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 351(1): 158-169.
26. Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol Rev 80(2): 717-766.
27. Schmidt JJ, Stafford RG. 2003. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 69(1): 297-303.
28. Schmidt JJ, Stafford RG, Millard CB. 2001. High-throughput assays for botulinum neurotoxin proteolytic activity: Serotypes A, B, D, and F. Anal Biochem 296(1): 130-137.
29. Siegel RW, Coleman JR, Miller KD, Feldhaus MJ. 2004. High efficiency recovery and epitope-specific sorting of an scFv yeast display library. J Immunol Methods 286(1-2): 141-153.
30. Singh BR. 2000. Intimate details of the most poisonous poison. Nat Struct Biol 7(8): 617-619.
31. Van Antwerp JJ, Wittrup KD. 2000. Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol Prog 16(1): 31-37.